Selzentry (Maraviroc, Celsentri): News & Research
- Maraviroc Showing Tantalising Promise as Microbicide in Preclinical Studies (February 19, 2010)
From aidsmap.com
- Maraviroc Does Not Boost Stalled CD4s in Virologically Suppressed People (February 18, 2010)
From National AIDS Treatment Advocacy Project
- Selzentry Now for First-Timers (January/February 2010)
In Positively Aware, from Test Positive Aware Network
- Maraviroc Gets FDA Nod as First-Line Antiretroviral in U.S. (November 20, 2009)
From U.S. Food and Drug Administration
- U.S. FDA Panel Backs Wider Use of Pfizer HIV Drug (October 9, 2009)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Pfizer HIV Drug Seems Safe for New Use -- FDA Staff (October 7, 2009)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Maraviroc Levels in Female Genital Tract May Support Drug's Potential in HIV Prophylaxis (August 2009)
In Journal of Acquired Immune Deficiency Syndromes
- Early Tests of Maraviroc as Microbicide Produce Less Activity Than Expected (July 23, 2009)
Preclinical ex-vivo tests of the entry inhibitor drug maraviroc as a possible microbicide have found that the drug only produced a moderate protective effect against HIV: a 50% to 60% inhibition of HIV infection of penile tissue and an 85% inhibition in colorectal tissue, when given at high doses.
From aidsmap.com
- Genetic Test Predicts Response to Maraviroc in Treatment-Experienced HIV Patients (July 22, 2009)
To read PDF, click here.
From British Columbia Centre for Excellence in HIV/AIDS
- Maraviroc Looks Better With New Trofile Test (Winter/Spring 2009)
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
- Traditional Approval and Label Changes for Selzentry (Maraviroc) (December 4, 2008)
From U.S. Food and Drug Administration
- IPM Reaches Landmark Agreement With Pfizer to Develop FDA-Approved Antiretroviral Drug as Vaginal Microbicide (January 30, 2008)
From International Partnership for Microbicides
- ICAAC: Maraviroc Failures Associated With Shifts From R5-Tropic to Mixed or X4-Tropic HIV (September 20, 2007)
From aidsmap.com
- IAS: Maraviroc Produces Best Results When Combined With Another Active Drug (August 14, 2007)
From aidsmap.com
- Clinical Data Show Pfizer's Antiretroviral Maraviroc Reduces HIV Viral Loads Among Treatment-Naive People, Company Says (July 26, 2007)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Maraviroc Underperforms Efavirenz in Treatment-Naive Study (July 25, 2007)
In 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from TheBodyPRO.com
- European Advisory Panel Recommends Approval of Pfizer's Antiretroviral Maraviroc, Company Says (July 23, 2007)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Pfizer Advises Maraviroc Dose Increase if Combined With Etravirine (July 20, 2007)
From aidsmap.com
- Held Up in U.S., First CCR5 Inhibitor Nears Approval in Europe (July 20, 2007)
From aidsmap.com
- Maraviroc Approval Is Delayed in United States (June 21, 2007)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Treatment Action Group Supports Maraviroc Approval (May 1, 2007)
From Treatment Action Group
|
Advertisement
|
Email
Glossary
